Tricyclic heterocycles as bet protein inhibitors
US-2016159817-A1 · Jun 9, 2016 · US
Tricyclic heterocycles as BET protein inhibitors
US9624241B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9624241-B2 |
| Application number | US-201514923105-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 26, 2015 |
| Priority date | Mar 15, 2013 |
| Publication date | Apr 18, 2017 |
| Grant date | Apr 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound which is 7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, or a pharmaceutically acceptable salt thereof. 2. A compound which is 7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one. 3. A compound which is (4S)-2-(4-acetylpiperazin-1-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine, or a pharmaceutically acceptable salt thereof. 4. A compound which is (4S)-2-(4-acetylpiperazin-1-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine. 5. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 6. A pharmaceutical composition comprising the compound of claim 2 and at least one pharmaceutically acceptable carrier. 7. A pharmaceutical composition comprising the compound of claim 3 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 8. A pharmaceutical composition comprising the compound of claim 4 and at least one pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
- C07D498/06Primary
Peri-condensed systems · CPC title
Peri-condensed systems · CPC title
ortho- or peri-condensed with heterocyclic ring systems · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9624241B2 cover?
- The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
- Who is the assignee on this patent?
- Incyte Corp, Incyte Holdings Corp
- What technology area does this patent fall under?
- Primary CPC classification C07D498/06. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).